Mimosa Therapeutics

Named for the high DMT-content Mimosa tenuiflora tree, MIMOSA Therapeutics is a private equity-backed Public Benefit Corporation (PBC) that uses advanced scientific techniques to produce “high-quality, natural entheogens at very affordable prices.” The company has a production facility in the Netherlands.

MIMOSA’s leadership includes well-known actors in the psychedelic and plant medicine fields such as co-founders Amanda Feilding (Director) and James (Jim) Keim (CEO), Chief Mycologist Alan Rockefeller, Chief Culture Officer James (Jim) Fadiman, and Chief Analytics Officer Felix Blei. Dr. Blei’s paper on the discovery of beta carbolines in several psilocybin mushroom (aka magic mushroom) species earned Psychedelic Science Review’s 2020 Editor’s Choice Award for the Best Study on Psychedelics and Nature.1

In a Proactive interview, CEO James Keim described how MIMOSA cultivates psilocybin-containing mushroom mycelium in microbrewer bioreactor vats, which they call “entheobrewers.” Mycelium contains all the alkaloids of the fruiting bodies (what are typically referred to as mushrooms). This method allows MIMOSA to create a product that is all-natural –in other words, made without synthetics or genetic modification– and conducive to predictable dosages. Because of this ability to standardize doses, MIMOSA’s products are especially valuable in scientific research. Mr. Keim explained to interviewer Christine Corrado, “We preserve our genetics in freezers that are down to about negative 80 [degrees], and this guarantees that any researcher who wants to come back can replicate a study.” The company can produce both pure psilocybin and psilocybin combined with complementary molecules that naturally occur in Psilocybe species, such as baeocystin

As a Public Benefit Corporation, Mimosa aims to center ethics and equitable access in its work. Initiatives stated on its website include transparency in sourcing, ingredients, development, etc., open publishing of core discoveries, commitments to “avoid capital that is not committed to ethical impact investment” and to set aside “a percentage of profits for conservation, indigenous reciprocity, and for safety and education.” These contributions include direct donations of money and Offerings (described as “therapeutics, sacrament, and test kits”) to low-income communities.